SOURCE: Parcell Laboratories
NATICK, MA--(Marketwired - Dec 19, 2013) - Dr. Keith Crawford first came across ELA® adult stem cells while doing research for his Ph.D. thesis in 1994, but it would be twelve years more before he would confirm the breakthrough stem cell discovery. When he did, he realized that his team discovered the adult stem cell platform with dozens of potential therapeutic applications in the growing field of regenerative medicine. In 2013, Dr. Crawford joined Parcell Laboratories to continue his research, and today that company announced that he has been promoted to Chief Visionary Officer.
The promotion recognizes Dr. Crawford's continued efforts to learn about the cell and explore the many potential therapies that its discovery might enable, according to the company. "Dr. Crawford is a passionate, dedicated scientist and a true leader in regenerative medicine and here at Parcell," said Pamela Layton, founder and CEO of Parcell Laboratories. "His work will continue to explore various uses of the cell. Most notably, he will be working on tumor tracking applications, as well as potential cancer treatments using the ELA stem cell."
Dr. Crawford earned his Ph.D. from Harvard University in 1997, and his M.D. from the University of Texas Medical School in 1986. His postdoctoral training and appointments include tenures at Howard University Hospital, where he served as surgical resident; the Boston Children's Hospital (Center for Blood Research), where he served as a postdoctoral fellow in pediatrics. Dr. Crawford also serves as an instructor at the Harvard Medical School; director of the Center for Molecular Orthopedics at Brigham and Women's Hospital; assistant faculty director in the Office of Diversity, Inclusion, and Community Partnership at Harvard Medical School, and a visiting professor at his alma mater, Prairie View A&M University, where he graduated summa cum laude. In addition, Dr. Crawford served as the scientific director of the STARS summer biomedical enrichment program at Brigham and Women's Hospital and as a scientific advisor for the Harvard Catalyst Biomedical Enrichment Program at Harvard Medical School.
"Human life is the most precious commodity in the world, and too often we lose sight of that," said Dr. Crawford. "Regenerative medicine and stem cell therapy have demonstrated tremendous long-term potential for saving lives, but also immediate practicality for improving lives. As we enter the age of personalized medicine, Parcell Labs is perfectly positioned to deliver groundbreaking but proven therapies based on the ELA stem cell that I was fortunate to co-discover."
Dr. Crawford holds several patents, including a recently awarded one for the ELA multipotent stem cell. He resides in Westwood, Mass.
About Parcell Laboratories
Parcell Laboratories, LLC, founded in 2008, develops novel therapeutics based on its patented adult stem cell platform technology, the ELA® cell. The ELA cell was discovered by scientists affiliated with the Brigham and Women's Hospital and Harvard Medical School, who demonstrated the vast potential of the technology in regenerative medicine. ELA cells are found in various tissues throughout the body and are characterized by a specific surface marker profile that set them apart from other adult stem cells. Based in Natick, Mass., the Company's state-of-the-art research, processing, storage and fulfillment facilities set the stage for the future of adult stem cells and regenerative medicine. For more information, visit www.parcelllabs.com. Parcell Laboratories is a member of the Parcell Group of companies, which also includes CellCure Trust LLC and Cellogx, LLC.